A Study of RO5036505 in Patients With Moderate to Severe Asthma

Roche logo

Roche

Status and phase

Withdrawn
Phase 2

Conditions

Asthma

Treatments

Drug: RO5036505
Drug: placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00967590
PP22666
2009-013379-23

Details and patient eligibility

About

This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma. Patients will be randomized to receive either RO5036505 (380mg iv infusion once weekly) or placebo for 8 weeks. Patients will be on a standardized inhaled corticosteroid/long-acting beta-agonist regimen during study treatment. Target sample size is 50-100 individuals.

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adult patients, 18-70 years of age
  • moderate to severe asthma for >/=2 years
  • ACQ score >/= 1.5
  • ICS and LABA regimen at moderate to high dose
  • non-smokers

Exclusion criteria

  • oral corticosteroid use within 4 weeks prior to screening
  • current escalating immunotherapy
  • acute infection/antibiotic therapy within 4 weeks prior to screening, or chronic infection
  • pulmonary disease other than asthma
  • therapy with any approved monoclonal antibody or biologic agent within 12 months prior to screening
  • previous exposure to investigational monoclonal antibodies or biologics

Trial design

0 participants in 2 patient groups, including a placebo group

1
Experimental group
Treatment:
Drug: RO5036505
2
Placebo Comparator group
Treatment:
Drug: placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems